GlassScriptPhysician profile
Joseph C Schwartz
NPI 1770586752
$2,462.03
in general payments reported to CMS, 2019-2025
14 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $81.95 · 2021: $281 · 2022: $446 · 2023: $355 · 2024: $436 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $836.94 | 2019-2025 | Vabysmo, Susvimo |
| Mallinckrodt Hospital Products INC. | $437.76 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $378.89 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $217.53 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $145.99 | 2023-2025 | Syfovre |
| Ivantis, INC | $138.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.36 | 2019-2021 | |
| Genentech, INC. | $58.59 | 2022-2023 | Vabysmo |
| Bausch & Lomb Americas INC. | $37.00 | 2022-2024 | Xipere |
| Dompe US, INC. | $30.47 | 2024 | Oxervate |
| Biogen, INC. | $29.18 | 2024 | Byooviz |
| Horizon Therapeutics Plc | $26.87 | 2019-2022 | |
| Coherus Oncology, INC. | $26.83 | 2022 | |
| Harrow Eye, LLC | $19.75 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.